Cargando…
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
INTRODUCTION: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD–MBD), and cardiovascular disease. The REN-001 and REN-002 phase II, multicenter, randomized studies examined safety, tolerability, and effects of sotatercept, an ActRIIA-IgG1...
Autores principales: | Coyne, Daniel W., Singh, Hem N., Smith, William T., Giuseppi, Ana Carolina, Connarn, Jamie N., Sherman, Matthew L., Dellanna, Frank, Malluche, Hartmut H., Hruska, Keith A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933454/ https://www.ncbi.nlm.nih.gov/pubmed/31891000 http://dx.doi.org/10.1016/j.ekir.2019.08.001 |
Ejemplares similares
-
Early chronic kidney disease-mineral bone disorder stimulates vascular calcification
por: Fang, Yifu, et al.
Publicado: (2013) -
Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014) -
Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients
por: Adragao, Teresa, et al.
Publicado: (2017) -
Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension
por: Joshi, Sachindra R., et al.
Publicado: (2022) -
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)